3C3B image
Deposition Date 2008-01-28
Release Date 2008-07-01
Last Version Date 2024-10-30
Entry Detail
PDB ID:
3C3B
Keywords:
Title:
Crystal Structure of human phosphoglycerate kinase bound to D-CDP
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: )
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.80 Å
R-Value Free:
0.24
R-Value Work:
0.16
R-Value Observed:
0.17
Space Group:
P 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Phosphoglycerate kinase 1
Gene (Uniprot):PGK1
Chain IDs:A, B
Chain Length:420
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Molecular basis for the lack of enantioselectivity of human 3-phosphoglycerate kinase
Nucleic Acids Res. 36 3620 3629 (2008)
PMID: 18463139 DOI: 10.1093/nar/gkn212

Abstact

Non-natural L-nucleoside analogues are increasingly used as therapeutic agents to treat cancer and viral infections. To be active, L-nucleosides need to be phosphorylated to their respective triphosphate metabolites. This stepwise phosphorylation relies on human enzymes capable of processing L-nucleoside enantiomers. We used crystallographic analysis to reveal the molecular basis for the low enantioselectivity and the broad specificity of human 3-phosphoglycerate kinase (hPGK), an enzyme responsible for the last step of phosphorylation of many nucleotide derivatives. Based on structures of hPGK in the absence of nucleotides, and bound to L and d forms of MgADP and MgCDP, we show that a non-specific hydrophobic clamp to the nucleotide base, as well as a water-filled cavity behind it, allows high flexibility in the interaction between PGK and the bases. This, combined with the dispensability of hydrogen bonds to the sugar moiety, and ionic interactions with the phosphate groups, results in the positioning of different nucleotides so to expose their diphosphate group in a position competent for catalysis. Since the third phosphorylation step is often rate limiting, our results are expected to alleviate in silico tailoring of L-type prodrugs to assure their efficient metabolic processing.

Legend

Protein

Chemical

Disease

Primary Citation of related structures